Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH
29 search results for:

EASD 2019 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 09-24-2019 | Type 2 diabetes | Podcast | Article

    How was it for you? The experts discuss EASD 2019

    Our clinical advisors discuss their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial.

  2. 09-29-2021 | EASD 2021 | News | Article

    Heterogeneous CVD risk demonstrated in people with type 2 diabetes

    As outlined at the virtual 57th EASD Annual Meeting, Jan Westerink (University Medical Center Utrecht, the Netherlands) and colleagues used the DIAL competing risk-adjusted model to predict long-term CVD risk using individual-level data from CAPTURE, a cross-sectional study of 9823 adults with type 2 diabetes from 13 countries across five continents in 2019.

    Author:
    Claire Barnard
    Published in:
    EASD Annual Meeting; Sept 27–Oct 1, 2021
  3. 04-01-2022 | DUKPC 2022 | News | Article

    CVD-focused SGLT2 inhibitor prescribing failing to take hold

    In 2018, the ADA/EASD consensus statement was published, placing SGLT2 inhibitors as a priority second-line (after metformin) glucose-lowering option for people with established CVD, particularly those with heart failure or kidney disease.

    Author:
    Eleanor McDermid
    Published in:
    DUKPC 2022; 28 Mar–1 Apr
  4. 10-01-2020 | EASD 2020 | Conference coverage | Article
    News in brief

    ​​​​​​​CAPTURE reveals CVD in a third of people with type 2 diabetes worldwide

    The global CAPTURE study shows that one in three people with type 2 diabetes in 2019 had cardiovascular disease, but few were taking antidiabetes medications with proven cardioprotective ability.

    Author:
    Eleanor McDermid
    Published in:
    EASD virtual meeting; 21–25 September 2020
  5. 09-25-2019 | Heart failure | EASD 2019 | Article

    Cardiorenal disease the earliest, most serious CV manifestation in type 2 diabetes

    Cardiorenal disease is the foremost cardiovascular complication in people with type 2 diabetes, researchers report at the 55th EASD Annual Meeting in Barcelona, Spain.

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  6. 09-17-2019 | Semaglutide | EASD 2019 | Article

    PIONEER data support oral semaglutide across a wide range of patients

    Researchers at the 55th EASD Annual Meeting in Barcelona, Spain, have presented primary data and subanalyses from a number of the PIONEER trials investigating the efficacy of oral semaglutide in people with type 2 diabetes.

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  7. 09-25-2019 | Hypoglycemia | EASD 2019 | Article

    Daytime hyperglycemia, nocturnal hypoglycemia remain problems for EDIC cohort

    By Eleanor McDermid medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  8. 09-18-2019 | Semaglutide | EASD 2019 | Article
    News in brief

    Semaglutide tops liraglutide in SUSTAIN 10

    By Claire Barnard m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September Diabetes Metab 2019; doi:10.1016/j.diabet.2019.101117

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September Diabetes Metab 2019; doi:10.1016/j.diabet.2019.101117
  9. 09-18-2019 | Semaglutide | EASD 2019 | Article

    SUSTAIN 8: Semaglutide outperforms canagliflozin as second-line therapy for type 2 diabetes

    By Claire Barnard medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September Lancet Diabetes Endocrinol 2019; doi:10.1016/S2213-8587(19)30311-0

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September Lancet Diabetes Endocrinol 2019; doi:10.1016/S2213-8587(19)30311-0
  10. 09-18-2019 | Vildagliptin | EASD 2019 | Article

    Trial results VERIFY first-line combination therapy for type 2 diabetes

    By Eleanor McDermid medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group Lancet 2019; doi:10.1016/S0140-6736(19)32131-2 EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    Lancet 2019; doi:10.1016/S0140-6736(19)32131-2 EASD 2019; Barcelona, Spain: 16–20 September
  11. 09-17-2019 | Continuous glucose monitoring | EASD 2019 | Article

    CGM benefits persist with long-term use

    By Eleanor McDermid medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September Diabetes Care 2019; doi:10.2337/dc19-0888

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September Diabetes Care 2019; doi:10.2337/dc19-0888
  12. 09-23-2019 | Children | EASD 2019 | Article

    RISE compares alpha, beta cells in youth vs adults with early type 2 diabetes

    By Eleanor McDermid medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  13. 09-20-2019 | Nephropathy | EASD 2019 | Article

    Mixed results for PRIORITY diabetic nephropathy trial

    By Eleanor McDermid medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  14. 09-19-2019 | Continuous glucose monitoring | EASD 2019 | Article

    Majority of MDI users improve glycemic outcomes with CGM

    By Eleanor McDermid medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  15. 09-19-2019 | Medications | EASD 2019 | Article

    Imeglimin shows promise for type 2 diabetes

    By Claire Barnard m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September John Wilding comments on study results highlighting that imeglimin, an agent targeting mitochondrial bioenergetics, may represent a novel therapeutic approach for type 2 diabetes (2:17).

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  16. 09-18-2019 | Pathophysiology | EASD 2019 | Article

    ‘Strikingly different’ drivers of early type 2 diabetes onset in Asians, Europeans

    By Eleanor McDermid medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  17. 09-18-2019 | Pathogenesis | EASD 2019 | Article

    Type 2 diabetes genetic liability manifests in early lipid changes

    By Eleanor McDermid medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  18. 09-18-2019 | Pathogenesis | EASD 2019 | Article

    Trial shortcomings make GABA benefits unclear in early type 1 diabetes

    By Eleanor McDermid medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  19. 09-18-2019 | Cardiovascular outcomes | EASD 2019 | Article

    Collaborative type 2 diabetes care model has lasting benefits

    By Claire Barnard m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September
  20. 09-17-2019 | Glycemic control | EASD 2019 | Article

    Suboptimal glycemic control shown in adults with type 1 diabetes

    By Claire Barnard m edwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group EASD 2019; Barcelona, Spain: 16–20 September

    Published in:
    EASD 2019; Barcelona, Spain: 16–20 September

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.